Trials / Completed
CompletedNCT03289208
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment
An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Mild or Moderate Renal Impairment Compared to Subjects With Normal Renal Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
To assess the pharmacokinetics of MCI-186 after a single intravenous infusion of 30mg/hour in subjects with mild or moderate renal impairment compared to subjects with normal renal function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MCI-186 | 30 mg of edaravone will be administered intravenously over 60 minutes. |
Timeline
- Start date
- 2016-10-27
- Primary completion
- 2018-04-16
- Completion
- 2018-04-20
- First posted
- 2017-09-20
- Last updated
- 2026-01-08
- Results posted
- 2020-02-28
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03289208. Inclusion in this directory is not an endorsement.